Tools for Practice Outils pour la pratique


#191 Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy


CLINICAL QUESTION
QUESTION CLINIQUE
Is sacubitril/valsartan (Entresto®) effective for systolic heart failure (HF)?


BOTTOM LINE
RÉSULTAT FINAL
Based on one randomized controlled trial (RCT), for every 36 patients with heart failure switched from ACE inhibitors to sacubitril/valsartan, one fewer will die and one fewer will be admitted for heart failure over 27 months. Beta-blockers and aldosterone antagonists should be offered first and continued concurrently.   



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
One RCT (PARADIGM-HF):1 8,399 patients with systolic HF, mean age 64, ~94% Class II/IIIB-type natriuretic peptide (BNP) ~250 pg/mL, ~7% North AmericanPatients switched from their ACE inhibitor to sacubitril/valsartan 200 mg (97 mg/103 mg) BID or enalapril 10 mg BID.  
  • At 27 monthssacubitril/valsartan significantly reduced: 
    • Cardiovascular death or HF hospitalization: 22% versus 27%, Number Needed to Treat (NNT)=22. 
    • Cardiovascular death: 13% versus 17%, NNT=32.  
    • HF hospitalization13% versus 16%, NNT=36.  
    • All-cause mortality17% versus 20%, NNT=36. 
    • Mean blood pressure ~3 mmHg lower. 
    • Fewer discontinuations for renal impairment: 0.7% versus 1.4%, NNT=143. 
  • Adverse EffectsOverall fewer with sacubitril/valsartan, 10.7% versus 12.3%, NNT=63. But increased: 
    • Symptomatic hypotension: 14% versus 9.2%, Number Needed to Harm (NNH)=20.  
    • Angioedema cases: 19 versus 10.  
  • Limitations: ~20% withdrew during run-in, stopped early (which can overestimate benefit and underestimate harm), and industry sponsored. 
Context: 
  • The usefulness of initiating therapy based on BNP levels is unknown as most heart failure patients have elevated BNP.2 
  • Concurrent therapy in PARADIGM-HF:1 
    • ~93% taking beta-blockers.  
    • ~Half taking aldosterone antagonists. 
  • ACE inhibitors, beta-blockers, and aldosterone antagonists each reduce all-cause mortality by ~20-30% versus placebo.3 
  • Based on PARADIGM-HF,1 guidelines recommend replacing ACE inhibitor/angiotensin receptor blockers with sacubitril/valsartan if on ACE inhibitors, beta-blockers and aldosterone antagonists with elevated natriuretic peptides or hospitalization for heart failure in the previous 12 months.4,5 
  • Starting dose is 50 mg (24 mg/26 mg) to 100 mg (49 mg/51 mg) BID with possible titration to 200 mg in 2-4 weeks.6 
    • ~40% of patients will need a dose reduction (but 1/3 will be able to go back to full dose).7 
  • Although not currently covered by many insurance plans, it is a recommended benefit.8 
    • Cost ~$250/month. 


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Evan Sehn BScPharm PharmD Candidate
  • Terrence McDonald MD MSc CCFP (SEM) Dip. Sport Med.
  • Adrienne J Lindblad BSP ACPR PharmD

1. McMurray JJ, Packer M, Desai AS, et al. N Engl J Med. 2014; (11):993-1004.

2. Latour-Pérez J, Coves-Orts FJ, Abad-Terrado C, et al. Eur J Heart Fail. 2006; 8(4):390-9.

3. Lindblad AJ, Allan GM. Can Fam Physician. 2014; 60:e104.

4. Moe GW, Ezekowitz JA, Lepage S, et al. Can J Cardiol. 2015; 31:3-16.

5. Howlett JG, Chan M, Ezekowitz JA, et al. Can J Cardiol. 2016; 32:296-310.

6. Novartis Pharmacueticals Canada Inc. ENTRESTO® Product Monograph. Available from: https://www.ask.novartispharma.ca/download.htm?res=entresto_scrip_e.pdf&resTitleId=1137. Last Accessed: March 28, 2017.

7. Vardeny O, Claggett B, Packer M, et al. Eur J Heart Fail. 2016; 18:1228-34.

8. Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Final Recommendation: sacubitril/valsartan. Available from: https://www.cadth.ca/sites/default/files/cdr/complete/SR0447_complete_Entresto-Mar-22_e.pdf. Last Accessed: June 7, 2017.

Authors do not have any conflicts of interest to declare.